CHEMM Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CHEMM from our risk checks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 479.40 |
| 52 Week High | DKK 616.00 |
| 52 Week Low | DKK 281.20 |
| Beta | 1.6 |
| 1 Month Change | -10.22% |
| 3 Month Change | -5.44% |
| 1 Year Change | 68.09% |
| 3 Year Change | -42.17% |
| 5 Year Change | 54.90% |
| Change since IPO | 2,079.09% |
Recent News & Updates
Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely
Apr 06
ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 08Recent updates
Getting In Cheap On ChemoMetec A/S (CPH:CHEMM) Is Unlikely
Apr 06ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 08What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?
Dec 12ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Nov 09We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings
Sep 18What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You
Jul 29Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%
Jul 29What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?
Jul 03Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%
Apr 15What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You
Mar 01What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?
Mar 01Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 08Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares
Dec 21Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?
Nov 15ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 17A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)
Sep 15At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?
Jun 20With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case
Jun 01Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors
Jan 24If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity
Oct 26Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?
Oct 05Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?
Jul 18Shareholder Returns
| CHEMM | DK Life Sciences | DK Market | |
|---|---|---|---|
| 7D | 4.6% | 6.4% | 2.3% |
| 1Y | 68.1% | -12.4% | -34.1% |
Return vs Industry: CHEMM exceeded the Danish Life Sciences industry which returned -12.4% over the past year.
Return vs Market: CHEMM exceeded the Danish Market which returned -34.1% over the past year.
Price Volatility
| CHEMM volatility | |
|---|---|
| CHEMM Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DK Market | 9.9% |
| 10% least volatile stocks in DK Market | 3.6% |
Stable Share Price: CHEMM has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: CHEMM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 184 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
ChemoMetec A/S Fundamentals Summary
| CHEMM fundamental statistics | |
|---|---|
| Market cap | DKK 8.34b |
| Earnings (TTM) | DKK 169.08m |
| Revenue (TTM) | DKK 459.54m |
49.3x
P/E Ratio18.2x
P/S RatioIs CHEMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEMM income statement (TTM) | |
|---|---|
| Revenue | DKK 459.54m |
| Cost of Revenue | DKK 41.04m |
| Gross Profit | DKK 418.51m |
| Other Expenses | DKK 249.43m |
| Earnings | DKK 169.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | 9.72 |
| Gross Margin | 91.07% |
| Net Profit Margin | 36.79% |
| Debt/Equity Ratio | 0.2% |
How did CHEMM perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/20 17:28 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kallum Titchmarsh | BofA Global Research |
| null null | Danske Bank |
| Simon Larsson | Danske Bank |